Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Porter

Showing results (121-130 of 159) with videos related to

Pageof 16
Sort By:
Bioorganic & Medicinal Chemistry Letters|February 17, 2009
Atropisomeric small molecule Bcl-2 ligands: determination of bioactive conformationJohn Porter, Andrew Payne, Ian Whitcombe, et al.
Blood|May 17, 2012
Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled studyAli T Taher, John Porter, Vip Viprakasit, et al.
American Journal of Hematology|April 28, 2011
Iron chelation adherence to deferoxamine and deferasirox in thalassemiaFelicia Trachtenberg, Elliott Vichinsky, Dru Haines, et al.
Haematologica|May 13, 2008
Inflammation and oxidant-stress in beta-thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trialPatrick B Walter, Eric A Macklin, John Porter, et al.
Bioorganic & Medicinal Chemistry Letters|December 9, 2008
Discovery of a novel series of quinoxalines as inhibitors of c-Met kinaseJohn Porter, Simon Lumb, Fabien Lecomte, et al.
The Journal of Trauma and Acute Care Surgery|August 8, 2019
Cold-stored whole blood: A better method of trauma resuscitation?Joshua Paul Hazelton, Jeremy W Cannon, Catherine Zatorski, et al.
Acta Haematologica|April 15, 2008
Patient-reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open-label phase II trialElliott Vichinsky, Zahra Pakbaz, Onyinye Onyekwere, et al.
The Lancet. Haematology|August 21, 2022
Mitapivat in adult patients with pyruvate kinase deficiency receiving regular transfusions (ACTIVATE-T): a multicentre, open-label, single-arm, phase 3 trialAndreas Glenthøj, Eduard J van Beers, Hanny Al-Samkari, et al.
Journal of Nursing Care Quality|April 7, 2025
Improving Efficiencies in STEMI Care via the DMAIC Framework: Report of a Successful Quality Improvement ProjectJohn Porter, Erin M Larson, Courtney E Bennett, et al.
Blood|January 19, 2019
A phase 1/2 ascending dose study and open-label extension study of voxelotor in patients with sickle cell diseaseJo Howard, Claire Jane Hemmaway, Paul Telfer, et al.
Pageof 16

Showing results (121-130 of 159) with videos related to

Sort By:
Pageof 16
Bioorganic & Medicinal Chemistry Letters|February 17, 2009
Atropisomeric small molecule Bcl-2 ligands: determination of bioactive conformationJohn Porter, Andrew Payne, Ian Whitcombe, et al.
Blood|May 17, 2012
Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled studyAli T Taher, John Porter, Vip Viprakasit, et al.
American Journal of Hematology|April 28, 2011
Iron chelation adherence to deferoxamine and deferasirox in thalassemiaFelicia Trachtenberg, Elliott Vichinsky, Dru Haines, et al.
Haematologica|May 13, 2008
Inflammation and oxidant-stress in beta-thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trialPatrick B Walter, Eric A Macklin, John Porter, et al.
Bioorganic & Medicinal Chemistry Letters|December 9, 2008
Discovery of a novel series of quinoxalines as inhibitors of c-Met kinaseJohn Porter, Simon Lumb, Fabien Lecomte, et al.
The Journal of Trauma and Acute Care Surgery|August 8, 2019
Cold-stored whole blood: A better method of trauma resuscitation?Joshua Paul Hazelton, Jeremy W Cannon, Catherine Zatorski, et al.
Acta Haematologica|April 15, 2008
Patient-reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open-label phase II trialElliott Vichinsky, Zahra Pakbaz, Onyinye Onyekwere, et al.
The Lancet. Haematology|August 21, 2022
Mitapivat in adult patients with pyruvate kinase deficiency receiving regular transfusions (ACTIVATE-T): a multicentre, open-label, single-arm, phase 3 trialAndreas Glenthøj, Eduard J van Beers, Hanny Al-Samkari, et al.
Journal of Nursing Care Quality|April 7, 2025
Improving Efficiencies in STEMI Care via the DMAIC Framework: Report of a Successful Quality Improvement ProjectJohn Porter, Erin M Larson, Courtney E Bennett, et al.
Blood|January 19, 2019
A phase 1/2 ascending dose study and open-label extension study of voxelotor in patients with sickle cell diseaseJo Howard, Claire Jane Hemmaway, Paul Telfer, et al.
Pageof 16